Scientific Posters

Toxicokinetics of Pirfenidone in Dogs Following Inhalation in a Nebulized Aerosol Formulation

Toxicokinetics of Pirfenidone in Dogs Following Inhalation in a Nebulized Aerosol Formulation

Comparison of the Pharmacokinetics of Four Different Dose- Frequency Combinations of AMZ001 (Diclofenac Gel 3.06%) with Voltaren® (Diclofenac Gel 1%) in Healthy Subjects in a Phase 1 Study

Comparison of the Pharmacokinetics of Four Different Dose- Frequency Combinations of AMZ001 (Diclofenac Gel 3.06%) with Voltaren® (Diclofenac Gel 1%) in Healthy Subjects in a Phase 1 Study

Efficient and Economical Preclinical Pharmacokinetic Analyses for Human Therapeutic Antibodies and Constructs, Using a Validated Human Immunoglobulin Immunoassay in Plasma of Mice, Rats, and Monkeys

Efficient and Economical Preclinical Pharmacokinetic Analyses for Human Therapeutic Antibodies and Constructs, Using a Validated Human Immunoglobulin Immunoassay in Plasma of Mice, Rats, and Monkeys

Pirfenidone and its Metabolites 5-Carboxy-Pirfenidone and 5-Hydroxy-Pirfenidone Toxicokinetics in Rats Following Inhalation of a Nebulized Aerosol Formulation

Pirfenidone and its Metabolites 5-Carboxy-Pirfenidone and 5-Hydroxy-Pirfenidone Toxicokinetics in Rats Following Inhalation of a Nebulized Aerosol Formulation

Design Of Total Anti-Vegf Assay Provides Simple Data Interpretation Of Anti-Vegf Therapeutic Study

Design Of Total Anti-Vegf Assay Provides Simple Data Interpretation Of Anti-Vegf Therapeutic Study

Development of a 10 color flow cytometric assay to assess binding of a monoclonal antibody (VB421) against IGF 1R in Peripheral Blood Mononuclear Cells (PBMCs) from patients with Thyroid Eye Disease

Development of a 10 color flow cytometric assay to assess binding of a monoclonal antibody (VB421) against IGF 1R in Peripheral Blood Mononuclear Cells (PBMCs) from patients with Thyroid Eye Disease

Determination of Mifepristone in Human Plasma by Automated On-Line SPE Combined with MS/MS

Determination of Mifepristone in Human Plasma by Automated On-Line SPE Combined with MS/MS

Embryo-Fetal Developmental Toxicokinetic Study of CBX129801, a Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Nephropathy, in Rats and Rabbits After Subcutaneous Injections

Embryo-Fetal Developmental Toxicokinetic Study of CBX129801, a Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Nephropathy, in Rats and Rabbits After Subcutaneous Injections

Phase 1 Pharmacokinetic (PK) Assessment of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies

Phase 1 Pharmacokinetic (PK) Assessment of ATI-1123, a Novel Human Serum Albumin-Stabilized Nanoparticle Docetaxel Liposomal Formulation, in Patients with Advanced Solid Malignancies

Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide Drug for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats

Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide Drug for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats

Toxicokinetics of ETI-385 and its Components ETI-382 and ETI-383, a Serotonin 5-HT1A Receptor Agonist for Treatment of Nausea and Vomiting, Following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs

Toxicokinetics of ETI-385 and its Components ETI-382 and ETI-383, a Serotonin 5-HT1A Receptor Agonist for Treatment of Nausea and Vomiting, Following Subcutaneous Injection of ETI-385 to CD-1 Mice and Beagle Dogs

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Neuropathy, in Rats and Monkeys After Subcutaneous Injections

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Neuropathy, in Rats and Monkeys After Subcutaneous Injections

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period

$Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)$

Pharmacokinetics of AC220 and its Active Metabolite AC886, a FLT-3 Inhibitor, Following Sequential Oral Dose Escalation to Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Effect of Food on the Pharmacokinetics of Ulifloxacin, a Fluoroquinolone for Bacterial Gastroenteritis Treatment, in Healthy Subjects After Oral Dosing of the Prodrug Prulifloxacin

Effect of Food on the Pharmacokinetics of Ulifloxacin, a Fluoroquinolone for Bacterial Gastroenteritis Treatment, in Healthy Subjects After Oral Dosing of the Prodrug Prulifloxacin

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period

Toxicokinetics of CBX129801, a Bio-active C-Peptide for Potential Replacement Therapy in Type 1 Diabetic Peripheral Neuropathy, Following Subcutaneous Injection of CBX129801 in Monkeys in a 9-Month Study with a 7-Week Recovery Period

Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats

Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-Peptide in Patients with Type 1 Diabetes Mellitus

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-Peptide in Patients with Type 1 Diabetes Mellitus

Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer

Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer

Use of Cold Compounds and High Resolution Mass Spectrometry to Quickly Characterize Drug Uptake in Cryopreserved Human Hepatocytes

Use of Cold Compounds and High Resolution Mass Spectrometry to Quickly Characterize Drug Uptake in Cryopreserved Human Hepatocytes

Validated Multi-site GLP-compliant Analysis of Solithromycin (SOLI) in Monkey Plasma Samples Following Filtration to Remove Potentially Active Anthrax Spores

Validated Multi-site GLP-compliant Analysis of Solithromycin (SOLI) in Monkey Plasma Samples Following Filtration to Remove Potentially Active Anthrax Spores

Pirfenidone and its Metabolites 5-Carboxy-Pirfenidone and 5-Hydroxy-Pirfenidone Toxicokinetics in Rats Following Inhalation of a Nebulized Aerosol Formulation

Pirfenidone and its Metabolites 5-Carboxy-Pirfenidone and 5-Hydroxy-Pirfenidone Toxicokinetics in Rats Following Inhalation of a Nebulized Aerosol Formulation

Toxicokinetics of Pirfenidone in Dogs Following Inhalation in a Nebulized Aerosol Formulation

Toxicokinetics of Pirfenidone in Dogs Following Inhalation in a Nebulized Aerosol Formulation

Comparison of the Pharmacokinetics of Four Different Dose-Frequency Combinations of AMZ001 (Diclofenac Gel 3.06%) with Voltaren® (Diclofenac Gel 1%) in Healthy Subjects in a Phase 1 Study

Comparison of the Pharmacokinetics of Four Different Dose-Frequency Combinations of AMZ001 (Diclofenac Gel 3.06%) with Voltaren® (Diclofenac Gel 1%) in Healthy Subjects in a Phase 1 Study

Efficient and Economical Preclinical Pharmacokinetic Analyses for Human Therapeutic Antibodies and Constructs, Using a Validated Human Immunoglobulin Immunoassay in Plasma of Mice, Rats, and Monkeys

Efficient and Economical Preclinical Pharmacokinetic Analyses for Human Therapeutic Antibodies and Constructs, Using a Validated Human Immunoglobulin Immunoassay in Plasma of Mice, Rats, and Monkeys

A Quantitative Method for Determining Hyaluronan Content in Plasma by LC/MS/MS and Plasma HA as a PharmacodynamicMarker for PEGylated-Hyaluronidase PH20 (PEGPH20) in a Phase 1b Trial for Pancreatic Ductal Adenocarcinoma

A Quantitative Method for Determining Hyaluronan Content in Plasma by LC/MS/MS and Plasma HA as a PharmacodynamicMarker for PEGylated-Hyaluronidase PH20 (PEGPH20) in a Phase 1b Trial for Pancreatic Ductal Adenocarcinoma

Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer

Pharmacokinetic Bioequivalence of ATI-0918 and DOXIL®/CAELYX® in Patients with Ovarian Cancer

Validated Multi-site GLP-compliant Analysis of Solithromycin (SOLI) in Monkey Plasma Samples Following Filtration to Remove Potentially Active Anthrax Spores

Validated Multi-site GLP-compliant Analysis of Solithromycin (SOLI) in Monkey Plasma Samples Following Filtration to Remove Potentially Active Anthrax Spores

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-peptide in Patients with Type 1 Diabetes Mellitus

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-peptide in Patients with Type 1 Diabetes Mellitus

Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats

Comparison of Encapsulated and Non-encapsulated Doxorubicin Pharmacokinetics Following Single Intravenous Administration of ATI-0918, an Encapsulated Liposomal Formulation, and DOXIL® in Female Rats

↑

USA HQ

2300 Englert Dr

Durham, NC, 27713

919-381-6097

Fax 919-381-6099

San Diego Laboratory

9050 Camino Santa Fe

San Diego, CA 92121

858-652-4600

Fax 858-652-4699

Brisbane Laboratory

37 Kent St, Woolloongabba

Queensland, 4102, Australia

USA HQ

2300 Englert Dr

Durham, NC, 27713

919-381-6097

Fax 919-381-6099

San Diego Laboratory

9050 Camino Santa Fe

San Diego, CA 92121

858-652-4600

Fax 858-652-4699

Brisbane Laboratory

37 Kent St,Woolloongabba

Queensland, 4102, Australia

Boston Laboratory

1320 Soldiers Field Road

Boston, MA, 02135

617-456-0700

Fax 617-456-0701

Boston Laboratory

1320 Soldiers Field Road

Boston, MA, 02135

617-456-0700

Fax 617-456-0701

European HQ

Lademannbogen 10

22339 Hamburg Germany

+49 405267790

Melbourne Laboratory

85 Commercial Road, Melbourne

Victoria, 3004, Australia

+61 3 9282 2184

Copyright © 2023 BioAgilytix Labs. All rights reserved. Terms of Use | Privacy Notice

European HQ

Lademannbogen 10

22339 Hamburg Germany

+49 405267790

Melbourne Laboratory

85 Commercial Road, Melbourne

Victoria, 3004, Australia

+61 3 9282 2184

Copyright © 2023 BioAgilytix Labs.

All rights reserved.

↑

Durham Lab (USA HQ)

2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099

Morrisville Lab

5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099

Boston Lab

1320 Soldiers Field Road

Boston, MA, 02135

Office 617-456-0700

Fax 617-456-0701

San Diego Lab

9050 Camino Santa Fe

San Diego, CA 92121

858-652-4600

Fax 858-652-4699

Hamburg Lab (EU HQ)

Lademannbogen 10

22339 Hamburg Germany

+49 405267790

Brisbane Lab

37 Kent St, Woolloongabba

Queensland, 4102, Australia

Melbourne Lab

85 Commercial Road, Melbourne

Victoria, 3004, Australia

03 9282 2184

Copyright © 2023 BioAgilytix Labs.

All rights reserved.
Terms of Use | Privacy Notice

Durham Lab (USA HQ)

2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099

Morrisville Lab

5927 S. Miami Blvd. Suite 100
Morrisville, NC 27703
919-381-6097
Fax 919-381-6099

Boston Lab

1320 Soldiers Field Road

Boston, MA, 02135

617-456-0700

Fax 617-456-0701

San Diego Lab

9050 Camino Santa Fe

San Diego, CA 92121

858-652-4600

Fax 858-652-4699

European HQ

Lademannbogen 10

22339 Hamburg Germany

+49 405267790

Brisbane Lab

37 Kent St,Woolloongabba

Queensland, 4102, Australia

Melbourne Lab

85 Commercial Road, Melbourne

Victoria, 3004, Australia

03 9282 2184

Copyright © 2023 BioAgilytix Labs.

All rights reserved.